Seminal Articles—Gastric Cancer

Based on our expert's review, here are the must-read articles for every oncologist about patients with gastric cancer.

Epidemiology

1. Kamineni A, Williams MA, Schwartz SM, et al. The incidence of gastric carcinoma in Asian migrants to the United States and their descendants. Cancer Causes Control. 1999;10(1):77-83.

2. Al-Refaie WB, Tseng JF, Gay G, et al. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008;113(3):461-469. Free

Risk Factors

3. Kubo A, Corley DA: Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):872-878. Free

4. Liu C, Russell RM: Nutrition and gastric cancer risk: an update. Nutr Rev. 2008;66(5):237-249.

5. Huang JQ, Sridhar S, Chen Y, et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114(6):1169-1179.

6. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151(2):121-128. Free

7. Uemura N, Okamoto S, Yamamoto S. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-789. Free

8. Trédaniel J, Boffetta P, Buiatti E, et al. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer. 1997;72(4):565-573.

9. Huntsman DG, Carneiro F, Lewis FR. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344(25):1904-1909. Free

Diagnosis and Staging

10. Botet JF, Lightdate CJ, Zauber AG, et al. Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT. Radiology. 1991;181:426-432.

11. Park SR, Lee JS, Kims CG, et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer. 2008;112(11):2368-2376. Free

12. Herrmann K, Ott K, Buck AK, et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med. 2007; 48(12):1945-1950. Free

13. Bentrem D, Gerdes H, Tang L, Brennan M, Coit D. Clinical correlation of endoscopic ultrasonograohy with pathological stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14(6):1853-1859.

14. Keswani RN, Early DS, Edmundowicz SA, et al. Routine PET does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. Gastrointest Endosc. 2009;69(7):1210-1217.

Surgery and Endoscopic Resection

15. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999; 340(12):908-914. Free

16. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9-10):1522-1530. Free

17. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439-449.

18. Soetikno R, Kaltenbac T, Yeh R, et al. Endoscopic mucosal resection for early cancers of the upper GI tract. J Clin Oncol. 2005;23(20):4490-4498.

19. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48(2):225-229. Free

20. Hartgrink HH, van de Velde CJ, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004; 22(11):2069-2077.

21. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93(5):559-563.

22. Sasako M, Sano T, Yamamoto S .D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer. N Engl J Med. 2008;359(5):453-462. Free

Palliative Surgery for Gastric Cancer

23. Jurnink SM, van Eijck CH, Steyerberg EW, et al. Stent versus gastrojujenostomy tube for palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7:18-27. Free

24. Vakil N, Morris AI, Macon N, et al. A prospective, controlled trial of covered epandable metal stents in the palliation of malignant esophageal obstruction of the gastroesophageal junction. Am J Gastroenterol. 2001;96(6):1791-1796.

Pathology

25. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.

26. Smith DD, Schwarz RR, Schwarz RE, et al. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US population database. J Clin Oncol. 2005;23(28):7114-7124.

Neoadjuvant and Peri-Operative Therapy

27. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med. 2006;335(1):11-20. Free

28. Ajani A, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953-3958.

29. Ychou M, Boige V, Pignon JP. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-1721.

Adjuvant Therapy

30. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001;345(1):725-30. Free

31. Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 29:2011 (suppl; abstr 4003).

32. Sasako M, Sakuramoto S, Katai H, et al. Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. J Clin Oncol. 2011;29(33):4387-4393.

33. Cascinu S, Labianca R, Barone C, et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst. 2007;99(8):601-607. Free

34. Bang Y, Kim YW, Yang H. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315-321.

35. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729-1737.

36. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268-273.

Metastatic Disease

Chemotherapy

37. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909.

38. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261-267.

39. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991-4997.

40. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46. Free

41. Van Cutsem E, Dicato M, Geva R, et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011;22(Suppl 5):v1-9. Free

42. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19(8):1450-1457. Free

43. Kang JH, Lee SI, Lim do H. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone. J Clin Oncol. 2012;30(13):1513-8.

44. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003; 26(1):37-41. Free

45. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23(24):5660-5667.

46. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-1442.

Biologics

47. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. J Clin Oncol. 2011;29:3968-3976.

48. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.